Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSFT

Go back to Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

B.Riley Reiterates Buy Rating on WAVE Life Sciences (WVE)

September 25, 2024 6:24 AM EDT

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $11.00 price target on WAVE Life Sciences (NASDAQ: WVE).

The analyst comments "In totality, we believe results exceeded our/investor expectations (9/18 initiation) and replicated the preclinical and early clinical datasets indicative of best-in-class exon skipping profile... More